Form 4: Recursion Pharmaceuticals COO Tina Marriott Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Tina Marriott, President and COO of Recursion Pharmaceuticals, exercised stock options and sold 6,000 shares of Class A Common Stock at an average price of $7.0008, pursuant to a pre-arranged 10b5-1 trading plan.
Summary
- On September 26, 2024, Tina Marriott, the President and COO of Recursion Pharmaceuticals, executed a transaction involving the company's Class A Common Stock.
- Marriott exercised stock options to acquire 6,000 shares at a price of $1.06 per share.
- Simultaneously, Marriott sold 6,000 shares at a weighted average price of $7.0008, with individual sales ranging from $6.84 to $7.16.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan established on March 1, 2024.
- Following these transactions, Marriott directly owns 521,138 shares of Class A Common Stock.
- Marriott also holds options to purchase a total of 1,639,049 shares of Class A Common Stock at various exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports insider trading activity under a pre-arranged plan. It doesn't inherently indicate positive or negative news about the company.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.
Risks
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The use of a 10b5-1 plan indicates a pre-planned and transparent approach to selling shares.
Comparison to Industry Standards
- Insider trading activity is common across the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also see regular Form 4 filings from their executives.
- The use of 10b5-1 plans is a standard practice to avoid accusations of illegal insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, depending on their perception of insider selling.
- The impact on employees, customers, suppliers, and creditors is likely to be negligible.
Key Dates
| Date | Description |
|---|---|
| 2018-07-16 | Annual Vesting Commencement Date for a stock option grant. |
| 2020-12-31 | Monthly Vesting Commencement Date for a stock option award. |
| 2022-02-04 | Date of stock option grant with an exercise price of $11.4 and expiration on 02/04/2032. |
| 2022-03-01 | Vesting start date for a stock option. |
| 2023-03-01 | Vesting start date for a stock option. |
| 2024-03-01 | Date the 10b5-1 trading plan was established. |
| 2024-09-26 | Date of the stock option exercise and share sale. |
| 2024-09-30 | Date of signature on the SEC Form 4 filing. |
| 2028-07-22 | Expiration date for a stock option. |
| 2030-12-30 | Expiration date for a stock option. |
| 2032-02-04 | Expiration date for a stock option. |
| 2033-02-01 | Expiration date for a stock option. |
| 2034-02-09 | Expiration date for a stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.